- |||||||||| INO-6145 / Inovio, PENNVAX-GP (HIV DNA vaccine) / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
Trial completion, Trial completion date, Trial primary completion date: Therapeutic Vaccination in Treated HIV Disease (clinicaltrials.gov) - May 19, 2021
P1/2, N=56, Completed,
Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> May 2021 | Trial primary completion date: Dec 2021 --> May 2021
- |||||||||| INO-6145 / Inovio, PENNVAX-GP (HIV DNA vaccine) / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
Enrollment closed: Therapeutic Vaccination in Treated HIV Disease (clinicaltrials.gov) - Feb 12, 2021
P1/2, N=56, Active, not recruiting,
Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> May 2021 | Trial primary completion date: Dec 2021 --> May 2021 Recruiting --> Active, not recruiting
- |||||||||| INO-6145 / Inovio, PENNVAX-GP (HIV DNA vaccine) / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
Trial completion date, Trial primary completion date: Therapeutic Vaccination in Treated HIV Disease (clinicaltrials.gov) - Oct 13, 2020
P1/2, N=60, Recruiting,
Recruiting --> Active, not recruiting Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||||||||| INO-6145 / Inovio, PENNVAX-GP (HIV DNA vaccine) / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
New P1/2 trial: Therapeutic Vaccination in Treated HIV Disease (clinicaltrials.gov) - Jul 30, 2018
P1/2, N=60, Recruiting,
|
